MediWound (MDWD) Competitors

Evolus (NASDAQ:EOLS) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.

Do insiders & institutionals have more ownership in EOLS or MDWD?

90.7% of Evolus shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 6.1% of Evolus shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is EOLS or MDWD more profitable?

Evolus has a net margin of -22.33% compared to MediWound's net margin of -142.29%. MediWound's return on equity of -82.17% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-22.33%	-847.60%	-22.15%
MediWound	-142.29%	-82.17%	-33.67%

Which has preferable earnings and valuation, EOLS or MDWD?

MediWound has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$248.33M	2.90	-$61.69M	-$0.91	-12.49
MediWound	$19.72M	9.85	-$6.72M	-$2.90	-6.21

Which has more volatility & risk, EOLS or MDWD?

Evolus has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Does the media prefer EOLS or MDWD?

In the previous week, Evolus had 2 more articles in the media than MediWound. MarketBeat recorded 3 mentions for Evolus and 1 mentions for MediWound. MediWound's average media sentiment score of 1.34 beat Evolus' score of 1.07 indicating that MediWound is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediWound	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer EOLS or MDWD?

Evolus presently has a consensus price target of $23.00, indicating a potential upside of 102.29%. MediWound has a consensus price target of $27.50, indicating a potential upside of 52.78%. Given Evolus' higher possible upside, equities research analysts clearly believe Evolus is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
MediWound	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in EOLS or MDWD?

MediWound received 42 more outperform votes than Evolus when rated by MarketBeat users. However, 72.58% of users gave Evolus an outperform vote while only 62.15% of users gave MediWound an outperform vote.

Company	Underperform	Outperform
Evolus	Outperform Votes 352 72.58%	Underperform Votes 133 27.42%
MediWound	Outperform Votes 394 62.15%	Underperform Votes 240 37.85%

Summary

Evolus beats MediWound on 10 of the 17 factors compared between the two stocks.